肿瘤细胞治疗研究
ALL SOURCES
Dual CAR-NK cells targeting PD-L1 and ErbB2 (HER2) exhibit cooperative CAR signaling and counteract solid tumor heterogeneity.
同时靶向 PD-L1 与 ErbB2 可通过对抗原异质性提供抵抗力并经协同激活放大抗肿瘤信号，增强 CAR-NK 细胞对难治性实体瘤的疗效。
Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
我们的结果表明，将NKAB抗体与表达激活型NKAR受体的效应细胞联合使用，是一种强大且多用途的策略，可同时增强肿瘤抗原特异性细胞毒性以及NKG2D-CAR和天然NKG2D介导的细胞毒性，这可能特别适用于靶向具有异质性靶抗原表达的肿瘤。
Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D
我们的结果表明，将携带活化NKAR受体的NK细胞与双特异性NKAB抗体联合使用，可实现灵活靶向，从而增强肿瘤抗原特异性细胞毒性并防止免疫逃逸。
Advancements in CAR-T Cell Therapy for Ovarian Cancer: Current Strategies and Future Directions.
嵌合抗原受体（CAR）T 细胞疗法已成为肿瘤学中的一种变革性方法，尤其在血液系统恶性肿瘤中。
Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeti
通过将IgG1抗体与靶向另一种肿瘤相关抗原并接合NKG2D作为第二NK细胞触发分子的抗体构建体相结合，双-双靶向策略可能具有前景。
共 5 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
